AI assistant
Candel Therapeutics, Inc. — Director's Dealing 2021
Jul 27, 2021
33336_dirs_2021-07-26_eea58c33-f107-4de8-be42-ddcedb860623.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26
Reporting Person: Manning Paul B (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Preferred Stock | $ | Common Stock (679158) | Indirect | ||
| Series B Preferred Stock | $ | Common Stock (553752) | Indirect | ||
| Warrants to purchase Common Stock | $6.81 | 2025-11-13 | Common Stock (679158) | Indirect | |
| Warrants to purchase Common Stock | $6.81 | 2025-11-13 | Common Stock (553752) | Indirect |
Footnotes
F1: The Series B Preferred Stock has no expiration date.
F2: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.